NCT01568203View on ClinicalTrials.gov

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

PHASE1TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Schizophrenia
Interventions
DRUG

AMG 579

3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)

DRUG

Placebo

Matching placebo control for AMG 579 at each dose level

Trial Locations (1)

91206

Research Site, Glendale

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY